Chemistry, Manufacturing, and Control Information for Human Gene Therapy Investigational New Drug Applications; Guidance for Industry; Availability, 5447-5448 [2020-01701]

Download as PDF Federal Register / Vol. 85, No. 20 / Thursday, January 30, 2020 / Notices 5447 TABLE 1—LIST OF INFORMATION COLLECTIONS APPROVED BY OMB—Continued OMB control number Title of collection Requirements Under the Comprehensive Smokeless Tobacco Health Education Act of 1986, as Amended by the Family Smoking Prevention and Tobacco Control Act .................................................................................. Electronic Drug Product Reporting for Human Drug Compounding Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act ..................................................................................................... Experimental Study on Measuring Consumer Comprehension of Displays of Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke .................................................................................... Medical Devices; Current Good Manufacturing Practice Quality System Regulation ............................................ Threshold of Regulation for Substances Used in Food-Contact Articles ............................................................... Regulations Restricting the Sale and Distribution of Cigarettes and Smokeless Tobacco to Protect Children and Adolescents ................................................................................................................................................... Format and Content Requirements for Over-the-Counter Drug Product Labeling ................................................. Product Jurisdiction: Assignment of Agency Component for Review of Premarket Applications .......................... Preparing a Claim of Categorical Exclusion or an Environmental Assessment for Submission to the Center for Food Safety and Applied Nutrition ....................................................................................................................... Hypertension Indication: Drug Labeling for Cardiovascular Outcome Claims ........................................................ Guidance for Tobacco Retailers on Tobacco Retailer Training Programs ............................................................. Dear Health Care Provider Letters: Improving Communication of Important Safety Information .......................... Requests for Feedback on Medical Device Submissions ....................................................................................... Data to Support Social and Behavioral Research as Used by the Food and Drug Administration ....................... Dated: January 24, 2020. Lowell J. Schiller, Principal Associate Commissioner for Policy. [FR Doc. 2020–01655 Filed 1–29–20; 8:45 am] BILLING CODE 4164–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Chemistry, Manufacturing, and Control Information for Human Gene Therapy Investigational New Drug Applications; Guidance for Industry; Availability Food and Drug Administration, HHS. ACTION: You may submit either electronic or written comments on Agency guidances at any time as follows: ADDRESSES: Electronic Submissions Notice of availability. The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance entitled ‘‘Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs); Guidance for Industry.’’ The guidance document provides sponsors of human gene therapy INDs with recommendations regarding CMC information to be submitted in an IND. The guidance document informs sponsors how to provide sufficient CMC information required to assure product safety, identity, quality, purity, and strength (including potency) of the investigational product. The guidance applies to human gene therapy products and to combination products that contain a human gene therapy in combination with a drug or device. SUMMARY: khammond on DSKJM1Z7X2PROD with NOTICES The announcement of the guidance is published in the Federal Register on January 30, 2020. DATES: [Docket No. FDA–2008–D–0205] AGENCY: The guidance announced in this notice finalizes the draft guidance of the same title dated July 2018 and supersedes the document entitled ‘‘Guidance for FDA Reviewers and Sponsors: Content and Review of Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs),’’ dated April 2008 (April 2008 guidance). VerDate Sep<11>2014 16:56 Jan 29, 2020 Jkt 250001 Submit electronic comments in the following way: • Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to https:// www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else’s Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on https://www.regulations.gov. PO 00000 Frm 00081 Fmt 4703 Sfmt 4703 Date approval expires 0910–0671 11/30/2022 0910–0827 11/30/2022 0910–0880 0910–0073 0910–0298 11/30/2022 12/31/2022 12/31/2022 0910–0312 0910–0340 0910–0523 12/31/2022 12/31/2022 12/31/2022 0910–0541 0910–0670 0910–0745 0910–0754 0910–0756 0910–0847 12/31/2022 12/31/2022 12/31/2022 12/31/2022 12/31/2022 12/31/2022 • If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see ‘‘Written/Paper Submissions’’ and ‘‘Instructions’’). Written/Paper Submissions Submit written/paper submissions as follows: • Mail/Hand Delivery/Courier (for written/paper submissions): Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. • For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in ‘‘Instructions.’’ Instructions: All submissions received must include the Docket No. FDA– 2008–D–0205 for ‘‘Chemistry, Manufacturing, and Control Information for Human Gene Therapy Investigational New Drug Applications; Guidance for Industry.’’ Received comments will be placed in the docket and, except for those submitted as ‘‘Confidential Submissions,’’ publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday. • Confidential Submissions—To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential E:\FR\FM\30JAN1.SGM 30JAN1 5448 Federal Register / Vol. 85, No. 20 / Thursday, January 30, 2020 / Notices khammond on DSKJM1Z7X2PROD with NOTICES with a heading or cover note that states ‘‘THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.’’ The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on https://www.regulations.gov. Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as ‘‘confidential.’’ Any information marked as ‘‘confidential’’ will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA’s posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: https:// www.govinfo.gov/content/pkg/FR-201509-18/pdf/2015-23389.pdf. Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to https:// www.regulations.gov and insert the docket number, found in brackets in the heading of this document, into the ‘‘Search’’ box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. You may submit comments on any guidance at any time (see 21 CFR 10.115(g)(5)). Submit written requests for single copies of the guidance to the Office of Communication, Outreach and Development, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Rm. 3128, Silver Spring, MD 20993–0002. Send one self-addressed adhesive label to assist the office in processing your requests. The guidance may also be obtained by mail by calling CBER at 1– 800–835–4709 or 240–402–8010. See the SUPPLEMENTARY INFORMATION section for electronic access to the guidance document. FOR FURTHER INFORMATION CONTACT: Sana F. Hussain, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Rm. 7301, Silver Spring, MD 20993–0002, 240– 402–7911. SUPPLEMENTARY INFORMATION: VerDate Sep<11>2014 16:56 Jan 29, 2020 Jkt 250001 I. Background FDA is announcing the availability of a document entitled ‘‘Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs); Guidance for Industry.’’ The guidance document provides sponsors of human gene therapy INDs with recommendations regarding CMC information to be submitted in an IND. The guidance document informs sponsors how to provide sufficient CMC information required to assure product safety, identity, quality, purity, and strength (including potency) of the investigational product (21 CFR 312.23(a)(7)(i)). The guidance applies to human gene therapy products and to combination products that contain a human gene therapy in combination with a drug or device. The field of gene therapy has progressed rapidly since FDA issued the April 2008 guidance. Therefore, FDA is updating the guidance to provide current FDA recommendations regarding the CMC content of a gene therapy IND. In addition, the guidance is organized to follow the structure of the FDA guidance on the Common Technical Document. In the Federal Register of July 12, 2018 (83 FR 32307), FDA announced the availability of the draft guidance of the same title. FDA received numerous comments on the draft guidance and those comments were considered as the guidance was finalized. In addition, editorial changes were made to improve clarity. The guidance announced in this notice finalizes the draft guidance dated July 2018. The guidance also supersedes the April 2008 guidance. Elsewhere in this issue of the Federal Register, FDA is announcing the availability of two other final guidances. In a separate document, FDA is announcing the availability of a document entitled ‘‘Long Term FollowUp After Administration of Human Gene Therapy Products; Guidance for Industry’’ and the availability of a document entitled ‘‘Testing of Retroviral Vector-Based Human Gene Therapy Products for Replication Competent Retrovirus During Product Manufacture and Patient Follow-up; Guidance for Industry.’’ This guidance is being issued consistent with FDA’s good guidance practices regulation (21 CFR 10.115). The guidance represents the current thinking of FDA on ‘‘Chemistry, Manufacturing, and Control Information for Human Gene Therapy Investigational New Drug Applications.’’ It does not establish any PO 00000 Frm 00082 Fmt 4703 Sfmt 4703 rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. II. Paperwork Reduction Act of 1995 This guidance refers to previously approved collections of information found in FDA regulations. These collections of information are subject to review by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501– 3521). The collections of information in 21 CFR part 211 have been approved under OMB control number 0910–0139; the collections of information in 21 CFR part 312 and Form FDA 1571 have been approved under OMB control number 0910–0014; the collections of information in 21 CFR part 601 have been approved under OMB control number 0910–0338; and the collections of information in 21 CFR part 1271 have been approved under OMB control number 0910–0543. III. Electronic Access Persons with access to the internet may obtain the guidance at either https://www.fda.gov/vaccines-bloodbiologics/guidance-complianceregulatory-information-biologics/ biologics-guidances or https:// www.regulations.gov. Dated: January 27, 2020. Lowell J. Schiller, Principal Associate Commissioner for Policy. [FR Doc. 2020–01701 Filed 1–29–20; 8:45 am] BILLING CODE 4164–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–1999–D–0081] Testing of Retroviral Vector-Based Human Gene Therapy Products for Replication Competent Retrovirus During Product Manufacture and Patient Follow-up; Guidance for Industry; Availability AGENCY: Food and Drug Administration, HHS. ACTION: Notice of availability. The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance entitled ‘‘Testing of Retroviral Vector-Based Human Gene Therapy Products for Replication Competent Retrovirus During Product Manufacture and Patient Follow-up; Guidance for Industry.’’ The guidance provides SUMMARY: E:\FR\FM\30JAN1.SGM 30JAN1

Agencies

[Federal Register Volume 85, Number 20 (Thursday, January 30, 2020)]
[Notices]
[Pages 5447-5448]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-01701]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2008-D-0205]

Chemistry, Manufacturing, and Control Information for Human Gene
Therapy Investigational New Drug Applications; Guidance for Industry;
Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of availability.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing
the availability of a final guidance entitled ``Chemistry,
Manufacturing, and Control (CMC) Information for Human Gene Therapy
Investigational New Drug Applications (INDs); Guidance for Industry.''
The guidance document provides sponsors of human gene therapy INDs with
recommendations regarding CMC information to be submitted in an IND.
The guidance document informs sponsors how to provide sufficient CMC
information required to assure product safety, identity, quality,
purity, and strength (including potency) of the investigational
product. The guidance applies to human gene therapy products and to
combination products that contain a human gene therapy in combination
with a drug or device.
The guidance announced in this notice finalizes the draft guidance
of the same title dated July 2018 and supersedes the document entitled
``Guidance for FDA Reviewers and Sponsors: Content and Review of
Chemistry, Manufacturing, and Control (CMC) Information for Human Gene
Therapy Investigational New Drug Applications (INDs),'' dated April
2008 (April 2008 guidance).

DATES: The announcement of the guidance is published in the Federal
Register on January 30, 2020.

ADDRESSES: You may submit either electronic or written comments on
Agency guidances at any time as follows:

Electronic Submissions

Submit electronic comments in the following way:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

Submit written/paper submissions as follows:
Mail/Hand Delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All submissions received must include the Docket No.
FDA-2008-D-0205 for ``Chemistry, Manufacturing, and Control Information
for Human Gene Therapy Investigational New Drug Applications; Guidance
for Industry.'' Received comments will be placed in the docket and,
except for those submitted as ``Confidential Submissions,'' publicly
viewable at https://www.regulations.gov or at the Dockets Management
Staff between 9 a.m. and 4 p.m., Monday through Friday.
Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential

[[Page 5448]]

with a heading or cover note that states ``THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.'' The Agency will review this copy, including
the claimed confidential information, in its consideration of comments.
The second copy, which will have the claimed confidential information
redacted/blacked out, will be available for public viewing and posted
on https://www.regulations.gov. Submit both copies to the Dockets
Management Staff. If you do not wish your name and contact information
to be made publicly available, you can provide this information on the
cover sheet and not in the body of your comments and you must identify
this information as ``confidential.'' Any information marked as
``confidential'' will not be disclosed except in accordance with 21 CFR
10.20 and other applicable disclosure law. For more information about
FDA's posting of comments to public dockets, see 80 FR 56469, September
18, 2015, or access the information at: https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852.
You may submit comments on any guidance at any time (see 21 CFR
10.115(g)(5)).
Submit written requests for single copies of the guidance to the
Office of Communication, Outreach and Development, Center for Biologics
Evaluation and Research (CBER), Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 71, Rm. 3128, Silver Spring, MD 20993-0002. Send
one self-addressed adhesive label to assist the office in processing
your requests. The guidance may also be obtained by mail by calling
CBER at 1-800-835-4709 or 240-402-8010. See the SUPPLEMENTARY
INFORMATION section for electronic access to the guidance document.

FOR FURTHER INFORMATION CONTACT: Sana F. Hussain, Center for Biologics
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 71, Rm. 7301, Silver Spring, MD 20993-0002, 240-
402-7911.

SUPPLEMENTARY INFORMATION:

I. Background

FDA is announcing the availability of a document entitled
``Chemistry, Manufacturing, and Control (CMC) Information for Human
Gene Therapy Investigational New Drug Applications (INDs); Guidance for
Industry.'' The guidance document provides sponsors of human gene
therapy INDs with recommendations regarding CMC information to be
submitted in an IND. The guidance document informs sponsors how to
provide sufficient CMC information required to assure product safety,
identity, quality, purity, and strength (including potency) of the
investigational product (21 CFR 312.23(a)(7)(i)). The guidance applies
to human gene therapy products and to combination products that contain
a human gene therapy in combination with a drug or device.
The field of gene therapy has progressed rapidly since FDA issued
the April 2008 guidance. Therefore, FDA is updating the guidance to
provide current FDA recommendations regarding the CMC content of a gene
therapy IND. In addition, the guidance is organized to follow the
structure of the FDA guidance on the Common Technical Document.
In the Federal Register of July 12, 2018 (83 FR 32307), FDA
announced the availability of the draft guidance of the same title. FDA
received numerous comments on the draft guidance and those comments
were considered as the guidance was finalized. In addition, editorial
changes were made to improve clarity. The guidance announced in this
notice finalizes the draft guidance dated July 2018. The guidance also
supersedes the April 2008 guidance.
Elsewhere in this issue of the Federal Register, FDA is announcing
the availability of two other final guidances. In a separate document,
FDA is announcing the availability of a document entitled ``Long Term
Follow-Up After Administration of Human Gene Therapy Products; Guidance
for Industry'' and the availability of a document entitled ``Testing of
Retroviral Vector-Based Human Gene Therapy Products for Replication
Competent Retrovirus During Product Manufacture and Patient Follow-up;
Guidance for Industry.''
This guidance is being issued consistent with FDA's good guidance
practices regulation (21 CFR 10.115). The guidance represents the
current thinking of FDA on ``Chemistry, Manufacturing, and Control
Information for Human Gene Therapy Investigational New Drug
Applications.'' It does not establish any rights for any person and is
not binding on FDA or the public. You can use an alternative approach
if it satisfies the requirements of the applicable statutes and
regulations.

II. Paperwork Reduction Act of 1995

This guidance refers to previously approved collections of
information found in FDA regulations. These collections of information
are subject to review by the Office of Management and Budget (OMB)
under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3521). The
collections of information in 21 CFR part 211 have been approved under
OMB control number 0910-0139; the collections of information in 21 CFR
part 312 and Form FDA 1571 have been approved under OMB control number
0910-0014; the collections of information in 21 CFR part 601 have been
approved under OMB control number 0910-0338; and the collections of
information in 21 CFR part 1271 have been approved under OMB control
number 0910-0543.

III. Electronic Access

Persons with access to the internet may obtain the guidance at
either https://www.fda.gov/vaccines-blood-biologics/guidance-compliance-regulatory-information-biologics/biologics-guidances or
https://www.regulations.gov.

Dated: January 27, 2020.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2020-01701 Filed 1-29-20; 8:45 am]
BILLING CODE 4164-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.